KR101900435B1 - 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 - Google Patents

인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 Download PDF

Info

Publication number
KR101900435B1
KR101900435B1 KR1020137001220A KR20137001220A KR101900435B1 KR 101900435 B1 KR101900435 B1 KR 101900435B1 KR 1020137001220 A KR1020137001220 A KR 1020137001220A KR 20137001220 A KR20137001220 A KR 20137001220A KR 101900435 B1 KR101900435 B1 KR 101900435B1
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137001220A
Other languages
English (en)
Korean (ko)
Other versions
KR20130086036A (ko
Inventor
로렌스 엠. 카우바르
스토테 엘스워쓰
윌리엄 우싱어
크리스타 마우린 맥커체온
잉-핑 지앙
펜 장
보 첸
기제트 스페린데
민하 박
오리트 푸르드
Original Assignee
트렐리스 바이오싸이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트렐리스 바이오싸이언스 인코포레이티드 filed Critical 트렐리스 바이오싸이언스 인코포레이티드
Publication of KR20130086036A publication Critical patent/KR20130086036A/ko
Application granted granted Critical
Publication of KR101900435B1 publication Critical patent/KR101900435B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020137001220A 2010-06-16 2011-06-16 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 Active KR101900435B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35549910P 2010-06-16 2010-06-16
US61/355,499 2010-06-16
PCT/US2011/040761 WO2011159938A2 (en) 2010-06-16 2011-06-16 High affinity human antibodies to human cytomegalovirus (cmv) gb protein

Publications (2)

Publication Number Publication Date
KR20130086036A KR20130086036A (ko) 2013-07-30
KR101900435B1 true KR101900435B1 (ko) 2018-09-20

Family

ID=45348879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137001220A Active KR101900435B1 (ko) 2010-06-16 2011-06-16 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체

Country Status (11)

Country Link
US (3) US9017668B2 (enExample)
EP (1) EP2582389B1 (enExample)
JP (2) JP6055763B2 (enExample)
KR (1) KR101900435B1 (enExample)
CN (1) CN103221063B (enExample)
AU (1) AU2011268277B2 (enExample)
BR (1) BR112012032182A2 (enExample)
CA (1) CA2839420C (enExample)
IL (1) IL223665B (enExample)
RU (1) RU2613421C2 (enExample)
WO (1) WO2011159938A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542308T3 (es) * 2008-03-10 2015-08-04 Theraclone Sciences, Inc. Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
JP5833565B2 (ja) 2009-12-23 2015-12-16 ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ ヒトサイトメガロウイルスに対する結合メンバー
KR101900435B1 (ko) * 2010-06-16 2018-09-20 트렐리스 바이오싸이언스 인코포레이티드 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11440951B2 (en) 2017-03-13 2022-09-13 The Government Of The United States, As Represented By The Secretary Of The Army Therapeutic antibodies to Marburg virus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114560A2 (en) * 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
US7595379B2 (en) * 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
ES2526343T3 (es) 2004-06-03 2015-01-09 Novimmune Sa Anticuerpos anti-CD3 y métodos de uso de los mismos
WO2007094423A1 (ja) 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009531273A (ja) * 2006-02-28 2009-09-03 オンコセラピー・サイエンス株式会社 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
CA2657123A1 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspottm applications
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN100575361C (zh) * 2007-04-28 2009-12-30 中国人民解放军第三军医大学野战外科研究所 抗人巨细胞病毒包膜糖蛋白b的人源化单链抗体
US20110171233A1 (en) * 2007-08-22 2011-07-14 Ribovax Biotechnologies S.A. Antibodies Against Human Cytomegalovirus (HCMV)
RU2364627C2 (ru) * 2007-11-06 2009-08-20 Власик Татьяна Николаевна Экспрессионный вектор для синтеза белков в клетках млекопитающих
JP2011517320A (ja) 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質
EP2352759B1 (en) * 2008-07-16 2017-11-01 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
KR101900435B1 (ko) * 2010-06-16 2018-09-20 트렐리스 바이오싸이언스 인코포레이티드 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114560A2 (en) * 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus

Also Published As

Publication number Publication date
AU2011268277B2 (en) 2016-10-27
AU2011268277A2 (en) 2013-07-25
WO2011159938A2 (en) 2011-12-22
IL223665B (en) 2020-01-30
JP6055763B2 (ja) 2016-12-27
CN103221063A (zh) 2013-07-24
CA2839420C (en) 2023-06-13
RU2613421C2 (ru) 2017-03-16
EP2582389A4 (en) 2014-01-08
RU2013101769A (ru) 2014-07-27
US10030069B2 (en) 2018-07-24
CA2839420A1 (en) 2011-12-22
EP2582389B1 (en) 2018-02-21
US20150252099A1 (en) 2015-09-10
CN103221063B (zh) 2016-08-24
AU2011268277A1 (en) 2013-01-31
US20120020980A1 (en) 2012-01-26
US9017668B2 (en) 2015-04-28
EP2582389A2 (en) 2013-04-24
BR112012032182A2 (pt) 2016-10-25
JP2017038612A (ja) 2017-02-23
WO2011159938A3 (en) 2012-04-19
KR20130086036A (ko) 2013-07-30
US20170204165A1 (en) 2017-07-20
JP2013531991A (ja) 2013-08-15
US9688744B2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
AU2020294246B2 (en) Antibodies, uses & methods
AU2019246763B2 (en) Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
JP7277047B2 (ja) 抗ヒトｖｉｓｔａ抗体およびその使用
KR101900435B1 (ko) 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
AU2016200359B2 (en) Neutralizing Anti-CCL20 Antibodies
KR101518081B1 (ko) Ｃ형 간염 바이러스(ｈｃｖ)에 대한 인간 항체 및 이것의 용도
AU2013262593B2 (en) ST2 antigen binding proteins
CA2703667C (en) Anti-rsv g protein antibodies
KR20230002261A (ko) 항-sars-cov-2 중화 항체 및 이의 사용 방법
KR101849738B1 (ko) 수동 인플루엔자 면역에 유용한 항체
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
KR20090127341A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 항체
KR20100087283A (ko) 항­ｒｓｖ 항체의 재조합 제조 방법
AU2022202539A1 (en) Antibodies, uses & methods
KR20080113223A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
CN114685652B (zh) 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用
TW202300526A (zh) 針對ｇｄｆ－１５的抗體
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
AU2020256828A1 (en) Anti-CD40 antibody and use thereof
KR20160072268A (ko) 항-efna4 항체-약물 접합체
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
AU2021209282B2 (en) Anti-Sars-Cov-2 Neutralizing Antibodies
US20250250359A1 (en) Terminal deoxynucleotidyl transferase antibodies and uses thereof
TW202309075A (zh) 對冠狀病毒s蛋白質具特異性之化合物及其用途
CN121045380A (zh) Cd19结合分子及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8